HomeAI · summaries
Storia in 7 fonti
Chamath Palihapitiya Said This To Eli Lilly's Gene Therapy That Slashes LDL Cholesterol Up To 62% - Eli L
Chamath Palihapitiya reacted on X after Eli Lilly's VERVE-102 showed strong Phase 1b LDL cholesterol reduction results.
Confronto fonti
6 prospettive sulla stessa storiaTimeline cronologica
- ·
morningstar.com
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting…
A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for…
- ·
statnews.com
Eli Lilly says Verve’s gene editor lowers cholesterol levels in early study
Eli Lilly said Monday that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a clinical trial.
- ·
biopharmadive.com
Early data for heart drug affirm Lilly’s billion-dollar bet on Verve
The base editing medicine lowered “bad” cholesterol levels along with a key protein, clearing the way for a Phase 2 study.
- ·
benzinga.com
Chamath Palihapitiya Said This To Eli Lilly's Gene Therapy That Slashes LDL Cholesterol Up To 62% - Eli L
Chamath Palihapitiya reacted on X after Eli Lilly's VERVE-102 showed strong Phase 1b LDL cholesterol reduction results.
- ·
endpoints.news
Lilly reports new data on PCSK9 base editing gene therapy from Verve buyout
Eli Lilly said a base editing gene therapy from its purchase of Verve Therapeutics delivered additional positive results in a Phase 1b trial, paving the way for a mid-stage test…
- ·
Pharmalittle: We're reading about a Lilly gene therapy for cholesterol, three new Lilly deals, and more
Eli Lilly reported that a high dose of its gene-editing therapy reduced cholesterol levels by 62% in participants in a Phase 1 clinical trial
- ·
arstechnica.com
Bad cholesterol slashed 62% by single dose of gene-editing drug in small trial
The interim Phase I trial data was only from 35 people, but results look good so far.
- ·
One dose of gene-editing drug cut bad cholesterol 62% for months in small trial
The interim Phase I trial data was only from 35 people, but results look good so far.
- ·
abcnews.com
New drug could be game changer for people with high cholesterol
Drugmaker Eli Lilly is testing a new experimental drug that could be a game changer for treating high cholesterol.